Editing Sertraline (section)

===Other indications===
Sertraline is approved for the treatment of [[post-traumatic stress disorder]] (PTSD).<ref name="DailyMed"/> The [[National Institute for Clinical Excellence]] recommends it for patients who prefer drug treatment to a psychological one.<ref name="NICE-PTSD">{{cite web |url=https://www.nice.org.uk/guidance/ng116/resources/posttraumatic-stress-disorder-pdf-66141601777861 |title=www.nice.org.uk }}</ref> Other guidelines also suggest sertraline as a first-line option for [[pharmacological therapy]].<ref name="pmid16734498"/><ref name="pmid12516310"/> When necessary, long-term pharmacotherapy can be beneficial.<ref name="pmid16734498">{{cite journal | vauthors = Davis LL, Frazier EC, Williford RB, Newell JM | s2cid = 35429551 | title = Long-term pharmacotherapy for post-traumatic stress disorder | journal = CNS Drugs | volume = 20 | issue = 6 | pages = 465–76 | year = 2006 | pmid = 16734498 | doi = 10.2165/00023210-200620060-00003 }}</ref> There are both negative and positive clinical trial results for sertraline, which may be explained by the types of [[psychological trauma]]s, symptoms, and [[comorbidity|comorbidities]] included in the various studies.<ref name="pmid25081580"/> Positive results were obtained in trials that included predominantly women (75%) with a majority (60%) having physical or sexual assault as the traumatic event.<ref name="pmid16734498"/> Somewhat contrary to the above suggestions, a meta-analysis of sertraline clinical trials for PTSD found it to be statistically superior to placebo in the reduction of PTSD symptoms but the effect size was small.<ref name="pmid25644881">{{cite journal |vauthors=Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, van Ommeren M, de Jong J, Seedat S, Chen H, Bisson JI |title=Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis |journal=Br J Psychiatry |volume=206 |issue=2 |pages=93–100 |date=February 2015 |pmid=25644881 |doi=10.1192/bjp.bp.114.148551 |doi-access=free }}</ref> Another meta-analysis relegated sertraline to the second line, proposing [[Trauma focused cognitive behavioral therapy|trauma focused psychotherapy]] as a first-line intervention. The authors noted that [[Pfizer]] had declined to submit the results of a negative trial for inclusion in the meta-analysis making the results unreliable.<ref name="pmid27126398">{{cite journal | vauthors = Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW | title = Psychotherapy Versus Pharmacotherapy for Posttraumatic Stress Disorder: Systemic Review and Meta-Analyses to Determine First-Line Treatments | journal = Depression and Anxiety | volume = 33 | issue = 9 | pages = 792–806 | date = September 2016 | pmid = 27126398 | doi = 10.1002/da.22511 | s2cid = 20190202 | url = https://digitalcommons.unl.edu/cgi/viewcontent.cgi?article=1167&context=usuhs | doi-access = free }}</ref>

Sertraline, when taken daily, can be useful for the treatment of [[premature ejaculation]].<ref>{{cite journal | vauthors = Abdel-Hamid IA | title = Pharmacologic treatment of rapid ejaculation: levels of evidence-based review | journal = Current Clinical Pharmacology | volume = 1 | issue = 3 | pages = 243–54 | date = September 2006 | pmid = 18666749 | doi = 10.2174/157488406778249352 }}</ref> A disadvantage of sertraline is that it requires continuous daily treatment to delay ejaculation significantly.<ref name="pmid17983899">{{cite journal | vauthors = Waldinger MD | title = Premature ejaculation: state of the art | journal = The Urologic Clinics of North America | volume = 34 | issue = 4 | pages = 591–9, vii–viii | date = November 2007 | pmid = 17983899 | doi = 10.1016/j.ucl.2007.08.011 }}</ref>

A 2019 [[systematic review]] suggested that sertraline may be a good way to control [[anger]], [[irritability]], and [[hostility]] in depressed patients and patients with other comorbidities.<ref name="pmid31126061">{{cite journal | vauthors = Romero-Martínez Á, Murciano-Martí S, Moya-Albiol L | title = Is Sertraline a Good Pharmacological Strategy to Control Anger? Results of a Systematic Review | journal = Behavioral Sciences| volume = 9 | issue = 5 | date = May 2019 | page = 57 | pmid = 31126061 | pmc = 6562745 | doi = 10.3390/bs9050057 | doi-access = free }}</ref>